miR-342 and Tamoxifen Resistance in Breast Cancer
Author Information
Author(s): Diana M Cittelly, Partha M Das, Nicole S Spoelstra, Susan M Edgerton, Jennifer K Richer, Ann D Thor, Frank E Jones
Primary Institution: University of Colorado Denver, School of Medicine
Hypothesis
Downregulation of miR-342 is associated with tamoxifen resistance in breast tumors.
Conclusion
Restoring miR-342 expression may help sensitize tamoxifen-resistant breast tumors to treatment.
Supporting Evidence
- miR-342 was significantly downregulated in tamoxifen-resistant cell lines.
- Restoring miR-342 expression sensitized resistant cells to tamoxifen-induced apoptosis.
- Patients with higher miR-342 levels had better responses to tamoxifen therapy.
Takeaway
This study found that a tiny molecule called miR-342 helps breast cancer cells respond to a medicine called tamoxifen, and when miR-342 is low, the cancer doesn't respond well.
Methodology
The study analyzed miRNA expression in breast cancer cell lines and patient tumors, comparing sensitive and resistant models.
Limitations
The small sample size of tumor samples limited the statistical power of the findings.
Participant Demographics
Patients with ER(+) breast tumors who underwent tamoxifen therapy.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website